Mereo BioPharma
MREO
71 hedge funds and large institutions have $283M invested in Mereo BioPharma in 2021 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 23 increasing their positions, 16 reducing their positions, and 10 closing their positions.
50% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 10
44% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 16
22% more call options, than puts
Call options by funds: $547K | Put options by funds: $447K
8% more funds holding
Funds holding: 66 → 71 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.15% less ownership
Funds ownership: 13.69% → 13.55% (-0.15%)
7% less capital invested
Capital invested by funds: $305M → $283M (-$21.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$9.21M |
| 2 |
SCM
Suvretta Capital Management
New York
|
+$7.66M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.14M |
| 4 |
TLP
Tri Locum Partners
New York
|
+$4.21M |
| 5 |
Holocene Advisors
New York
|
+$2.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$14.4M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$14.3M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$4.42M |
| 4 |
Millennium Management
New York
|
-$3.1M |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$1.96M |
MREO Hedge Fund Activity: Q2 2021 in Review
71 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q2 2021, worth a combined $283M — down 7% from $305M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new MREO positions and 10 closed out — a net gain of 5 holders — while 23 added to existing stakes and 16 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $9.21M. The largest seller was Perceptive Advisors, cutting an estimated $14.4M.
- 71 institutional investors held Mereo BioPharma (MREO) as of Q2 2021, up from 66 in Q1 2021.
- Funds reported $283M of Mereo BioPharma stock for Q2 2021, down 7% quarter-over-quarter.
- 15 funds opened new Mereo BioPharma positions in Q2 2021 and 10 closed out, a net change of +5 holders.
- The largest Mereo BioPharma buyer in Q2 2021 was Rubric Capital Management (New York), an estimated $9.21M added.
- The largest Mereo BioPharma seller in Q2 2021 was Perceptive Advisors, an estimated $14.4M sold.
Based on aggregated 13F filings for Q2 2021.